Your session is about to expire
← Back to Search
Paxlovid for COVID-19 (CanTreatCOVID Trial)
CanTreatCOVID Trial Summary
This trial aims to test the effectiveness of various treatments for non-hospitalized Covid-19 patients in Canada, comparing them to usual care. Outcomes include hospitalization and death, and time to recovery.
CanTreatCOVID Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowCanTreatCOVID Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.CanTreatCOVID Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I or my caregiver cannot give informed consent.I am over 50 or have a chronic condition or a weakened immune system.I can start the study treatment within 5 days of showing COVID-19 symptoms.You have tested positive for SARS-CoV-2, and can provide a picture of the positive test result.I have been in the hospital or emergency department for over 24 hours.I am already on a study drug or cannot take one due to health reasons.You are currently in another clinical trial for treating COVID-19 with a different medicine that might not work well with the one in this study.
- Group 1: Paxlovid
- Group 2: Control group
- Group 3: Other Emerging Interventions (arm 3)
- Group 4: Other Emerging Interventions (arm 4)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there evidence to suggest that Other Emerging Interventions (arm 4) is a safe treatment option for individuals?
"Due to the high level of efficacy and safety data that is present, our experts at Power rated Other Emerging Interventions (arm 4) a 3 on a scale from 1 to 3. This reflects its status as being in Phase 3 trials."
Are recruitment efforts for this experiment currently underway?
"It appears that clinicaltrials.gov does not list this particular trial as accepting participants at the moment, even though it was initially posted on December 1st 2022 and last modified on November 9th 2022. Nonetheless, there are over a thousand other trials seeking enrolment right now."
Share this study with friends
Copy Link
Messenger